Jump to content

Lindy Durrant

Add links
From Wikipedia, the free encyclopedia

Lindy Durrant
Alma materUniversity of Manchester
Paterson Institute for Cancer Research
Scientific career
InstitutionsUniversity of Nottingham
Scancell Ltd

Lindy Durrant is a British immunologist who is Professor of Cancer Immunotherapy at the University of Nottingham and Chief Scientific Officer and Chief Executive Officer of the UK AIM listed biotech company Scancell Ltd. Durrant's work focusses on harnessing the immune system to treat cancer and infectious disease. Across her career Durrant has developed a panel of monoclonal antibodies which recognise tumour associated glycans, pioneered novel antibody engineering technology to enhance the avidity of monoclonal antibodies as well as developed a number of different cancer vaccine platforms to target cancers such as melanoma, triple negative breast cancer, head and neck cancer amongst others.

Early life and education

[edit]

Durrant was an undergraduate student at the University of Manchester, where she studied biochemistry. She moved to the medical school, where she started working on cancer chemotherapy at the Paterson Institute for Cancer Research.[citation needed]

Research and career

[edit]

In 1983, Durrant joined the University of Nottingham as a postdoctoral scientist and continues to work at the University. She now holds the position of Professor of Cancer Immunotherapy as well as heading up the Nottingham University Therapeutic Antibody Centre (NUTAC) which produces monoclonal antibodies for cancer therapy. In 1997 Durrant founded the company Scancell - a biotechnology company focussed on harnessing the immune system to treat cancer.[1][2] Through her work at Scancell, Durrant has gone on to develop two separate platforms to treat cancer through the stimulation of T cells to kill tumour cells. Firstly, a modular DNA vaccine platform ImmunoBody which was successfully trialled in melanoma (see SCIB1)[3] as well as a peptide based cancer vaccine Moditope which targets stress-induced post-translational modifications.[4] Both of these vaccines harness the immune system by inducing killer CD8 T cells and cytotoxic CD4 T cells to clear cancer cells from the body. She has also developed a number of different monoclonal antibodies which target tumour associated glycans,[5] as well as identifying unique sequence residues in the Fc region that enable monoclonal antibodies to self-associate upon target recognition, resulting in more potent, high avidity antibodies.[6]

During the COVID-19 pandemic Durrant and collaborators from the University of Nottingham and Nottingham Trent University created two COVID-19 vaccines[7] based on the ImmunoBody DNA vaccine platform. These vaccines were designed to induce both neutralising antibody and T-cell responses directly against the covid-19 N- and S-proteins which in comparison to first-generation vaccines could help protect patients against different variants of Covid-19 as well as more broadly against other beta-coronaviruses.[8][9][10] The vaccines are administered via spring-powered injectors which deliver a stream of fluid.[8] It is expected that these vaccines would be able to induce a strong T-cell response against the conserved N-protein which would help achieve longer lasting immunity.[11] The vaccines, which were supported by InnovateUK funding underwent clinical trials in 2021.[12][8]

Awards and honours

[edit]
  • 2019 Swedish Society of Oncology Waldenstrom Prize[13]

Selected publications

[edit]
  • Nicholas F S Watson; Judith M. Ramage; Zahra Madjd; Ian Spendlove; Ian Ellis; John H Scholefield; Lindy G Durrant (1 January 2006). "Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis". International Journal of Cancer. 118 (1): 6–10. doi:10.1002/IJC.21303. ISSN 0020-7136. PMID 16003753. Wikidata Q53851520.
  • Ekaterina S. Jordanova; Ekaterina S. Jordanova; Arko Gorter; et al. (1 April 2008). "Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?". Clinical Cancer Research. 14 (7): 2028–2035. doi:10.1158/1078-0432.CCR-07-4554. ISSN 1078-0432. PMID 18381941. Wikidata Q54539424.
  • Nicholas F S Watson; Ian Spendlove; Zahra Madjd; Roger McGilvray; Andrew R Green; Ian O Ellis; John H Scholefield; Lindy G Durrant (1 March 2006). "Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients". International Journal of Cancer. 118 (6): 1445–1452. doi:10.1002/IJC.21510. ISSN 0020-7136. PMID 16184547. Wikidata Q50753300.

References

[edit]
  1. ^ "COMPANY - Scancell". www.scancell.co.uk. Retrieved 28 April 2022.
  2. ^ "From flying taxis to painless vaccines: seven businesses to watch this year". The Guardian. 1 January 2022. Retrieved 29 April 2022.
  3. ^ "SCIB1 clinical trial". ClinicalTrials.gov. 13 July 2022.
  4. ^ "MODI-1 Clinical Trial". 17 May 2022.
  5. ^ Tivadar, Silvana T.; McIntosh, Richard S.; Chua, Jia Xin; Moss, Robert; Parsons, Tina; Zaitoun, Abed M.; Madhusudan, Srinivasan; Durrant, Lindy G.; Vankemmelbeke, Mireille (March 2020). "Monoclonal Antibody Targeting Sialyl-di-Lewisa-Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential". Molecular Cancer Therapeutics. 19 (3): 790–801. doi:10.1158/1535-7163.MCT-19-0221. ISSN 1538-8514. PMID 31871270. S2CID 209461473.
  6. ^ Vankemmelbeke, Mireille; McIntosh, Richard S.; Chua, Jia Xin; Kirk, Thomas; Daniels, Ian; Patsalidou, Marilena; Moss, Robert; Parsons, Tina; Scott, David; Harris, Gemma; Ramage, Judith M. (15 August 2020). "Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement". Cancer Research. 80 (16): 3399–3412. doi:10.1158/0008-5472.CAN-19-3599. ISSN 1538-7445. PMC 7611157. PMID 32532823.
  7. ^ Locker, Joseph (26 April 2020). "Nottingham scientists identify parts of coronavirus which may lead to vaccine". NottinghamshireLive. Retrieved 29 April 2022.
  8. ^ a b c "As Covid mutates, the vaccine makers are adapting too". The Guardian. 11 December 2021. Retrieved 29 April 2022.
  9. ^ "COVID-19: New vaccine in development has 'insurance' against coronavirus mutations". Sky News. Retrieved 29 April 2022.
  10. ^ "British scientists to trial new Covid vaccine with 'insurance' against mutant variants". inews.co.uk. 14 February 2021. Retrieved 29 April 2022.
  11. ^ Le Bert, Nina; Tan, Anthony T.; Kunasegaran, Kamini; Tham, Christine Y. L.; Hafezi, Morteza; Chia, Adeline; Chng, Melissa Hui Yen; Lin, Meiyin; Tan, Nicole; Linster, Martin; Chia, Wan Ni (August 2020). "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls". Nature. 584 (7821): 457–462. doi:10.1038/s41586-020-2550-z. ISSN 1476-4687. PMID 32668444. S2CID 220580925.
  12. ^ "Covid-19 DNA vaccine trial". 30 May 2022.
  13. ^ "Professor Lindy Durrant receives Waldenstr̦m award РCompany Announcement - FT.com". markets.ft.com. Retrieved 28 April 2022.


Retrieved from "https://en.wikipedia.org/w/index.php?title=Lindy_Durrant&oldid=1181286095"